Introduction
Multiple myeloma (MM) is a clonal B-cell neoplasia characterized by the accumulation of malignant plasma cells within the bone marrow, in close contact with stromal cells. Several autocrine or paracrine soluble factors can promote myeloma cell survival and proliferation 1 . Interleukin (IL)-6, which is mainly produced by cells of the tumor microenvironment, is a major myeloma growth factor 2 . Interferon alpha (IFN-α), insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) can also promote the survival or proliferation of myeloma cells [3] [4] [5] [6] [7] . The inhibition of myeloma cell growth factors may have clinical applications, eventually in combination with other drugs. For example, anti-IL-6 MoAb may lead to tumor regression in some advanced myeloma patients 8, 9 .
In order to identify new myeloma cell growth factors, we recently compared gene expression profiles of myeloma cells with those of normal plasmablasts and peripheral blood B cells [10] [11] [12] . Interestingly, the TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) and BCMA (B-cell maturation antigen) genes coding for two receptors of BAFF (B-cell activating factor, also called BLys) 13, 14 were highly expressed in malignant plasma cells 10, 11 . BAFF is a TNF family member essentially expressed by monocytes, macrophages, dendritic cells and some T cells 15 . It is produced as both a membrane-bound and a proteolytically cleaved soluble protein 13, 14 . A third receptor for BAFF, called BAFF-R, was recently identified 16 . The expression of BCMA and BAFF-R is B-cell-specific, whereas TACI is also found on a subset of activated T cells 15 . Finally, BAFF shares significant homology with a proliferation-inducing ligand (APRIL), which is expressed at a low level by normal lymphoid and myeloid cells, and at a high level by a variety of human HAL author manuscript inserm-00129502, version 1 cancers 17, 18 . APRIL, which is directly secreted without cell surface expression, binds to BCMA and TACI but not to BAFF-R 15 .
Several studies have indicated that BAFF is a survival factor for both immature, naive, and activated B cells 15 . The production of BAFF by myeloid dendritic cells in response to innate immune signals was shown to promote T-cell-independent immunoglobulin class switching and to sustain survival of extrafollicular plasmablasts 19 . BAFF-transgenic mice develop mature B-cell hyperplasia with autoimmune manifestations, especially production of autoantibodies 15 . Moreover, dysregulation of the BAFF pathway seems to be involved in autoimmunity in humans 15 . On the contrary, BAFF-or BAFF-R-deficient mice and mice treated with TACI-Fc or BCMAFc display severe loss of mature B cells 16 .
The role of APRIL is less well characterized. Recent reports have shown that APRIL provides survival and activation signals to normal B and T cells [20] [21] [22] . In addition, APRIL is highly expressed in several tumor tissues and stimulates growth of tumor cells in vitro and in vivo 17 .
The signal transduction pathways driven by BAFF and APRIL are not fully characterized. The activation of nuclear factor (NF)-κB by TACI, BCMA and BAFF-R 23 is consistent with the antiapoptotic role of BAFF since NF-κB enhances the transcription of several cell survival genes 24, 25 . Depending on the B-cell maturation stage, BAFF was reported to induce the antiapoptotic proteins Bcl-2, A1, and Bcl-XL and to reduce the pro-apoptotic protein Bak 23, 26, 27 . BAFF also activates JNK, Elk-1, p38 kinase, AP-1 and NF-AT in various models 15 .
The striking roles of BAFF, APRIL, and their receptors in normal B-cell homeostasis and in several tumor models raise the possibility that they may be involved in the pathogenesis of B-cell malignancies. Recent studies reported the aberrant expression of BAFF and APRIL by tumor B cells isolated from a subset of patients with chronic lymphoid leukemia, suggesting the existence of an autocrine survival loop in this disease 28, 29 . In vitro, a BCMA-Fc fusion protein is able to enhance apoptosis of B-CLL cells 29 . Sera from 26 patients with myeloma at diagnosis, 10 patients with PCL, and 9 agerelated healthy individuals were collected as described previously 32 .
mRNA analysis
We generated cDNA with 2 µg total RNA using the Superscript II reverse (APRIL), 58°C (BCMA), 60°C (TACI), 61°C (BAFF-R) and 60°C (β2M), 1 min at 72°C, followed by a final extension of 10 min at 72°C. Reaction products were electrophoresed on a 1.5% agarose gel.
Flow cytometry analysis
The overall expression of receptors for BAFF on HMCLs was evaluated by incubating 450 nm and standard curves were generated using known concentrations of recombinant human BAFF or APRIL. The sensitivity of the ELISA was 1.5 ng/ml for BAFF and 3 ng/ml for APRIL. The intra-assay variability of the ELISA was determined by measuring serum samples from seven patients in two separate experiments and was less than 14% for BAFF and less than 17% for APRIL.
Western blot analysis
HMCLs were starved overnight in RPMI 1640-1% bovine serum albumin (BSA) without IL-6. Cells were lysed in 10 mM tris-HCl (pH 7.05), 50 mM NaCl, 50 mM NaF, 30 mM sodium pyrophosphate (NaPPi), 1% Triton X-100, 5 µM ZnCl 2 , 100 µM 
Statistical analysis
Statistical significance was tested using a non parametric Wilcoxon test for pairs or a Student t test for pairs.
Results

BCMA, TACI and BAFF-R expression in malignant and normal plasma cells
RT-PCR analysis indicated that 13 out of 13 HMCLs expressed BCMA according to our microarray results ( Figure 1A ) 10, 11 . The expression pattern of TACI and BAFF-R was more heterogeneous. As shown in Figure 1A , TACI and BAFF-R were expressed, respectively, by 8 out of 13 and 9 out of 13 HMCLs. Unlike DCs, purified B cells expressed BCMA, TACI, and BAFF-R as reported 33 . We next looked for the expression in primary myeloma cells of six patients with intramedullary myeloma (patients 1-6) and of five patients with plasma cell leukemia (PCL) (patients 7-11).
BCMA RNA was detected in 11 out of 11 samples ( Figure 1A ). TACI and BAFF-R were simultaneously expressed by 8 out of 11 primary myeloma samples.
Expression of BAFF and APRIL receptors was found in 5 out of 5 in vitro generated normal plasmablasts. In particular, BCMA and TACI were detected at a high level whereas BAFF-R was less expressed. These results are in agreement with our Affymetrix data 10, 11 and with the recent study of Avery et al 34 ( Figure 1A ).
To confirm the membrane expression of receptors for BAFF, we used a biotinylated human BAFF-murine CD8 fusion protein, which binds to TACI, BCMA and BAFF-R.
In agreement with previous studies, this BAFF-murine CD8 did not label monocyte- ( Figure 1A ). In addition, we confirmed the presence of membrane receptors on primary myeloma cells and normal plasmablasts ( Figure 1C ).
BAFF and APRIL expression in malignant and normal plasma cells
Since an autocrine production of APRIL and BAFF was previously reported in several tumor models 17, 28, 29 , Figure 3C ). Conversely, TACI-Fc had no effect on IL-6-induced proliferation that was completely inhibited by an anti-IL-6 MoAb ( Figure 3C ). These data indicate that BAFF and APRIL myeloma cell growth factors are able to support the long-term growth of cytokine-dependent HMCLs.
Autocrine BAFF or APRIL are involved in the autonomous growth of cytokineindependent HMCLs
As BAFF or APRIL are growth factors for IL-6-dependent HMCLs and are produced by some autonomously growing HMCLs, we investigated whether BAFF/APRIL could be autocrine myeloma growth factors. We used RPMI8226 and L363 HMCLs that expressed BAFF and/or APRIL together with their receptors (Figures 1 and 2) . The autonomous proliferation of L363 and RPMI8226 cells was blocked by TACI-Fc, which neutralizes both BAFF and APRIL (Figure 4) . Adding an excess of recombinant BAFF and APRIL abrogated the inhibitory effect of TACI-Fc. These data indicated that a BAFF/APRIL autocrine loop is involved in the autonomous growth of some HMCLs.
BAFF and APRIL rescue myeloma cells from dexamethasone-induced apoptosis
We next sought to determine whether BAFF or APRIL could protect myeloma cells from the apoptosis induced by dexamethasone (DEX), a potent drug for MM treatment. As indicated in Figure 5A , DEX induced apoptosis in RPMI 8226 and L363
HMCLs. Both BAFF and APRIL significantly protected the RPMI 8226 HMCL from DEX-induced apoptosis (respectively, P = .001 and P = .0002; n = 5). The same results were obtained with L363 (respectively, P = .0007 and P = .001; n = 5). In fact, both BAFF and APRIL were as potent as IL-6 in protecting myeloma cells from DEXinduced apoptosis ( Figure 5A ).
We next investigated whether BAFF and APRIL could protect primary myeloma cells from DEX-induced apoptosis. Since purified myeloma cells are highly susceptible to spontaneous apoptosis in vitro, myeloma cells were cultured in the presence of their bone-marrow environment. In addition, recombinant IL-6 was added to reduce the variability resulting from the heterogeneous endogenous IL-6 production in cultured tumor samples 35 . As shown in Figure 5B , DEX reduced the median number of viable myeloma cells of eight patients by 58% (P = .03, n = 8). BAFF and APRIL enhanced survival of myeloma cells in the presence of DEX (respectively, P = .01 and P = .01; n = 8) yielding a number of malignant plasma cells that was not statistically different between DEX + BAFF, DEX + APRIL, and the control group ( Figure 5B ).
BAFF/APRIL inhibitor induces apoptosis of primary myeloma cells
Our data showing that BAFF and APRIL are survival factors for malignant plasma cells suggest that new therapeutic agents inhibiting BAFF/APRIL may be promising for myeloma treatment. We thus investigated the effect of the TACI-Fc fusion protein, able to block BAFF and APRIL, on primary myeloma cell survival and on drugsensitization. Primary myeloma cells were cultured with their bone marrow environment and recombinant IL-6. Detailed results obtained with six patients are shown in Table 1 . TACI-Fc significantly reduced the median number of viable myeloma cells by 48% (P = .028, n = 6). TACI-Fc also potentiated the inhibitory effect of DEX or B-E8 anti-IL-6 MoAb (respectively, P = .028, P = .046; n = 6). When the three inhibitors were used together, a 90% reduction of viable myeloma cells was observed within 4 days of culture ( Figure 6A ). Of interest, the non myeloma cells present in the culture wells were unaffected by these three inhibitors (results not shown).
Signal transduction and antiapoptotic protein regulation by BAFF or APRIL
As shown in Figure 7A , BAFF and APRIL induced a rapid phosphorylation of AKT and a late phosphorylation of MAPK in three myeloma cell lines (XG-13, XG-14 and RPMI8226), whereas no phosphorylation of STAT3 was detected. IL-6 induced the phosphorylation of STAT3, MAPK, and AKT, in agreement with previous data 36, 37 .
We also looked for NF-κB signaling, as there is accumulating evidence that BAFF and APRIL activate NF-κB transcription factors in B cells 33, [38] [39] [40] . We found that BAFF and APRIL, like TNF-α , enhanced NF-κB binding activity in XG-13 and RPMI8226 cells, whereas IL-6 induced a weak and transient activation of NF-κB, in agreement with previous studies 41 ( Figure 7B ). For XG-14 cells that biologically responded only to APRIL, we found that APRIL, unlike BAFF, enhanced NF-κB binding activity.
Interestingly, an inhibitor of PI3K/AKT (Ly 294002) abrogated the proliferation of XG-13 cells induced by BAFF or APRIL. A peptide inhibitor of the NF-κB pathway (SN50)
also inhibited BAFF or APRIL-induced myeloma cell proliferation, unlike the corresponding inactive peptide ( Figure 7C ).
We then studied the regulation by BAFF or APRIL of three Bcl-2 family antiapoptotic members (Mcl-1, Bcl-2, and Bcl-xL) known to be involved in growth factor-mediated myeloma cell survival or in BAFF-mediated survival in B cells [42] [43] [44] [45] [46] [47] . BAFF and APRIL induced an upregulation of Mcl-1 and Bcl-2 in XG-13 and RPMI8226 cells, whereas only APRIL increased Mcl-1 and Bcl-2 levels in XG-14 cells. In contrast, no change was noted in Bcl-xL protein expression ( Figure 8A and B). IL-6 increased Mcl-1 but neither Bcl-2 nor Bcl-xL levels according to our previous studies 45 .
Level of circulating BAFF and APRIL in sera of patients with MM
To further assess the biological relevance of our data, we looked for levels of soluble BAFF and APRIL in the sera of 36 patients with MM and nine age-related healthy individuals. Results shown in Figure 9 demonstrated that BAFF or APRIL median serum levels were increased, respectively, 4.2-fold (P = .02) and 5.9-fold in patients (P = 6.10 -9
) compared to healthy individuals.
Discussion
Accumulating experimental evidence supports the notion that BAFF is essential for the survival of normal immature and mature B cells 15 as well as normal plasmablatic cells 34 . BAFF plays a key role in the survival of B CLL tumor cells 28, 29 . In addition, APRIL stimulates the growth of some human and murine tumor cell lines in vitro and in vivo 17 . As BAFF/APRIL receptor genes are overexpressed in malignant plasma cells 10, 11 , our aim was to look for a role played by BAFF and APRIL in MM.
We demonstrate here that BAFF and APRIL are growth factors for two myeloma cell lines that highly expressed TACI and BAFF-R and whose survival is completely dependent upon addition of exogenous growth factors. APRIL is also a growth factor for a third cell line, XG-14, which expressed only TACI, unlike BAFF-R. We also show that an autocrine loop involving BAFF, APRIL and their receptors is involved in the autonomous growth of two well-known HMCLs, L363 and RPMI8226. BAFF and APRIL contribute to the survival of primary myeloma cells cultured together with their bone-marrow environment and these two factors prevent DEX-induced apoptosis in primary myeloma cells. Since the initial submission of this manuscript, another paper also indicated that BAFF and APRIL are myeloma cell growth factors 48 . Altogether, the current data and this paper extend previous reports indicating that BAFF/APRIL are involved in various B-cell neoplasias, in particular B-CLL and follicular lymphoma [28] [29] [30] , and in autoimmune diseases such as Sjögren's syndrome and systemic lupus Novak et al reported that all myeloma cells they tested bound soluble BAFF 48 . In this study, BAFF-R was not detectable on the cell surface of their HMCLs using an anti-BAFF-R antibody, whereas purified primary myeloma cells expressed BAFF-R. Thus, these data and our results indicate that we cannot yet draw firm conclusions on the respective role of TACI and BAFF-R in myeloma cells that express the two receptor genes, i.e, the majority of purified primary myeloma cells.
In order to better understand the effect of BAFF and APRIL on myeloma cells, we examined intracellular signaling pathways. BAFF was reported to induce NF-κB activation in B cells 23 and an overexpression of BCMA in human 293 cells activates the Rel/NF-κB, JNK, Elk-1, and p38 kinase transcription factors 56, 57 . . IGF-1 also activates NF-κB 41 . We show here that neither BAFF nor APRIL was able to induce STAT3 phosphorylation but did activate ERK1/2 and PI3K/Akt pathways. An inhibitor of PI3K/AKT abrogated the growth of myeloma cells induced by BAFF and APRIL. Of interest, BAFF and APRIL were also able to efficiently activate NF-κB, as was TNFα. Finally, we found that NF-κB activation was critical for the myeloma cell proliferation activity of BAFF or APRIL since it was dramatically blocked by an NF-κB peptide inhibitor.
BAFF and APRIL induced an upregulation of Bcl-2 and Mcl-1 antiapoptotic proteins in myeloma cells, whereas the level of Bcl-xL remained unchanged. In murine B cells, the survival effect of BAFF was associated with induction of A1, Bcl-2 and Bcl-xL 23, 26, 27 . This is in agreement with the activation of NF-κB, which enhances the transcription of a number of antiapoptotic genes, including A1, Bcl-2, Bcl-xL, cIAP2
and cFLIP. Previously, we demonstrated that among ten antiapoptotic and pro- A. Expression of BCMA, TACI, and BAFF-R mRNA was analyzed by RT-PCR in 13
HMCLs, in CD138 + purified primary myeloma cells from six patients with intramedullary MM (1-6) and five patients with plasma cell leukemia (7) (8) (9) (10) (11) , and in five normal in-vitro generated polyclonal plasmablastic cells (PPC). B cells and dendritic cells (DC) were used as positive and negative controls, respectively.
B.
Cell surface expression of receptors for BAFF by HMCLs was determined by flow cytometry using a biotinylated human BAFF-murine CD8 fusion protein and phycoerythrin-conjugated streptavidin.
C. Cell surface expression of receptors for BAFF by primary myeloma cells and PPC was determined by flow cytometry using a biotinylated human BAFF-murine CD8 fusion protein and phycoerythrin-conjugated streptavidin. A. XG-13, XG-14 and RPMI8226 cells were starved overnight before culture with no cytokine, or with IL-6 (30 ng/ml), BAFF (800 ng/ml) or APRIL (800 ng/ml) for 6 hours in RPMI-1% BSA. At the end of the culture, cells were immediately lysed and assayed for Bcl-2 family antiapoptotic protein expression using Western blot analysis.
In this experiment, STAT3 expression was used as loading protein control.
Blots of three independent experiments were scanned and the values were normalized using STAT3-band intensities as internal standards. Results are the median values for the three main Bcl-2-family members expressed in the XG-13
HMCLs starved of IL-6 and cultured for 6 hours with no cytokine, or with IL-6 (30 ng/ml), BAFF (800 ng/ml) or APRIL (800 ng/ml).
* Indicates a significant increase in expression with a Student t test for pairs (P < .05). 
